Skip to main content

Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes.

Citation
Montesanto, A., et al. “Erythropoietin (Epo) Haplotype Associated With All-Cause Mortality In A Cohort Of Italian Patients With Type-2 Diabetes.”. Scientific Reports, p. 10395.
Center University of Alabama at Birmingham
Author Alberto Montesanto, Anna Rita Bonfigli, Maria De Luca, Paolina Crocco, Paolo Garagnani, Elena Marasco, Chiara Pirazzini, Cristina Giuliani, Fabio Romagnoli, Claudio Franceschi, Giuseppe Passarino, Roberto Testa, Fabiola Olivieri, Giuseppina Rose
Abstract

Type-2 Diabetes (T2D), diabetic complications, and their clinical risk factors harbor a substantial genetic component but the genetic factors contributing to overall diabetes mortality remain unknown. Here, we examined the association between genetic variants at 21 T2D-susceptibility loci and all-cause mortality in an elderly cohort of 542 Italian diabetic patients who were followed for an average of 12.08 years. Univariate Cox regression analyses detected age, waist-to-hip ratio (WHR), glycosylated haemoglobin (HbA1c), diabetes duration, retinopathy, nephropathy, chronic kidney disease (CKD), and anaemia as predictors of all-cause mortality. When Cox proportional hazards multivariate models adjusted for these factors were run, three erythropoietin (EPO) genetic variants in linkage disequilibrium (LD) with each other (rs1617640-T/G, rs507392-T/C and rs551238-A/C) were significantly (False Discovery Rate < 0.1) associated with mortality. Haplotype multivariate analysis revealed that patients carrying the G-C-C haplotype have an increased probability of survival, while an opposite effect was observed among subjects carrying the T-T-A haplotype. Our findings provide evidence that the EPO gene is an independent predictor of mortality in patients with T2D. Thus, understanding the mechanisms by which the genetic variability of EPO affects the mortality of T2D patients may provide potential targets for therapeutic interventions to improve the survival of these patients.

Year of Publication
2019
Journal
Scientific reports
Volume
9
Issue
1
Number of Pages
10395
Date Published
12/2019
ISSN Number
2045-2322
DOI
10.1038/s41598-019-46894-2
Alternate Journal
Sci Rep
PMID
31316151
PMCID
PMC6637129
Download citation